Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib, Rituximab, and Lenalidomide in First-Line Marginal Zone Lymphoma
NCT07299331Not yet recruiting
- Sponsor
- Zhengzhou University
- Start
- Jan 2026
- Primary completion
- Apr 2031
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
01
Overview
Open-label, single-arm trial of zanubrutinib in marginal zone lymphoma (MZL), sponsored by Zhengzhou University. Primary endpoint: Complete Response Rate at 2 years. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
zanubrutinib
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT07299331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07299331.